Jeanette E. Eckel-Passow, Ph.D., develops and evaluates statistical methods for genome-wide omics data. This includes experimental design, normalization and statistical analysis methods for mRNA expression microarrays, protein mass spectrometry, copy number variation, and RNA and DNA sequencing.
Dr. Eckel-Passow has extensive statistical consulting experience in both clinical and basic science research. Her primary focus is the identification of molecular biomarkers for brain and kidney cancer.
Dr. Eckel-Passow is the biostatistics core director for the Mayo Clinic Brain Cancer Specialized Program of Research Excellence (SPORE) grant. She is also a principal investigator on an R21 grant from the National Institutes of Health to evaluate the genomics of progression to metastasis in clear cell renal cell carcinoma.
- Statistical methodology for genome-wide omics data.
- Glioma risk. Dr. Eckel-Passow collaborates with Robert B. Jenkins, M.D., Ph.D., to subtype gliomas based on acquired genetic alterations and to identify germline risk variants stratified by molecular subtype.
- Prognostic biomarkers for clear cell renal cell carcinoma. Dr. Eckel-Passow collaborates with Alexander S. Parker, Ph.D., to identify prognostic biomarkers for clear cell renal cell carcinoma. The objective is to develop a multivariable model that stratifies patients according to their risk level.
- Metastatic clear cell renal cell carcinoma. Dr. Eckel-Passow studies the molecular mechanisms that drive metastatic progression.
Significance to patient care
Dr. Eckel-Passow's goal is to provide experimental design guidance and statistical analysis methods to advance cancer research at Mayo Clinic.